Clinical Research
Filter News
Found 121,249 articles
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Teladoc Health Completes Merger with LivongoCombination Creates the Global Leader in Whole-Person Virtual Care
10/30/2020
Teladoc Health (NYSE: TDOC), the global leader in whole person virtual care, today announced that it has completed its merger with Livongo. The milestone marks completion of the most significant blending of capabilities and talent in the history of digital health. By joining the market leaders in virtual care and applied health signals, the combined company becomes the only consumer and healthcare provider partner to span a person’s entire health
-
Appili Therapeutics Joins Dr. Reddy’s, Global Response Aid, and FUJIFILM in Advancing Avigan® Tablets for the Potential Treatment of COVID-19
10/30/2020
Consortium brings together world-class and globally coordinated clinical development, commercialization, cGMP manufacturing, and logistics expertise to accelerate the deployment and availability of Avigan® tablets for the potential treatment and prevention of COVID-19
-
Havn Life Sciences to Support the First Modern Psilocybin Depression Study in Germany With MIND Foundation
10/30/2020
Havn Life Sciences Inc. (CNSX:HAVN)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce it has signed on to support ground-breaking research with the MIND Foundation on a study on depression and psilocybin.
-
OliX Pharmaceuticals Announces FDA Clearance of the IND to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial for Hypertrophic Scars
10/30/2020
Potential first-in-class treatment for hypertrophic scars with no FDA-approved medicines to to-date Phase 2a trial follows the successful completion of OliX’s Phase 1 trial in the U.K. in November 2019 OliX retains global rights to develop and commercialize OLX10010 outside Asia
-
Erbi Biosystems raises $3.8M to expand their platform of microfluidic bioprocess and bioreactor equipment, which enables ultra-high cell density and continuous processing
10/30/2020
Erbi Biosystems, a transformative microfluidic bioprocess instrumentation company based on technology developed at MIT , announced today the closing of a finance round which brings the total investment received to nearly $4M . The round was led by Jaguar Biotech. "This new funding allows us to expand manufacturing, sales and s
-
BioAgilytix Bioanalytical Lab Welcomes the Phadia 200 to Its Hamburg Laboratory
10/30/2020
BioAgilytix is thrilled to announce the addition of a new diagnostics tool to their growing list of cutting-edge bioanalysis instruments. The Phadia™ 200 is a powerhouse of a machine, in a compa
-
Cerevel Therapeutics Announces First Patients Dosed in all Phase 3 Trials of Tavapadon for the Treatment of Parkinson’s Disease
10/30/2020
Company developing investigational treatment for both newly diagnosed patients and those with a more advanced form of the disease in need of adjunctive therapy
-
Chinese Digital Health Platform for Women Voycare Inc. Introduces New Features to Provider Portal
10/30/2020
Voycare, Inc. is pleased to announce new features to the Provider side portal of its Chinese-language digital health platform for women.
-
BioFlorida Recognizes Florida's Contribution to Fight COVID-19
10/30/2020
Hundreds of life science industry leaders virtually convened at the BioFlorida Annual Conference to celebrate and share successes around efforts to test, treat, and prevent COVID-19
-
Olympus Launches Two New ERCP Stone Management Devices
10/30/2020
Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today the launch of its StoneMasterV and Vo
-
BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization
10/30/2020
Enrollment to cease immediately; topline data anticipated in H1 2021
-
Minimally Invasive Ellipsys System Creates Fused, Permanent Vascular Access for Dialysis
10/30/2020
A new case report published in the Journal of Vascular Surgery provides one of the first known opportunities to directly visualize the permanent and fused connection (anastomosis) that is created with the minimally invasive Ellipsys® Vascular Access System.
-
The McQuade Center for Strategic Research and Development Enters Collaboration Agreement with Rugen Holdings (Cayman) Limited to Develop Novel Treatment for Patients with Diverse Psychiatric Disorders
10/30/2020
The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announced today that it has entered an agreement with Rugen Holdings (Cayman) Limited, doing business as Rugen Therapeutics (Rugen), a pre-clinical biotechnology company focused on the development of novel treatments for central nervous system (CNS) disorders.
-
REGN-COV2 Independent Data Monitoring Committee Recommends Holding Enrollment in Hospitalized Patients with High Oxygen Requirements and Continuing Enrollment in Patients with Low or No Oxygen Requirements
10/30/2020
The IDMC also recommends continuation of enrollment in the REGN-COV2 outpatient trial Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patie
-
FDA Publishes List of Essential Medicines, Medical Countermeasures, Critical Inputs Required by Executive Order
10/30/2020
As the U.S. Food and Drug Administration continues our work to address the current pandemic, we are also looking ahead to prepare for the next potential public health emergency. A recent executive order directed the agency, in co
-
Sana Biotechnology Announces Acquisition of Oscine
10/30/2020
Sana will leverage Oscine's technologies to develop stem cell derived therapies for CNS disorders Steve Goldman, M.D., Ph.D., joins Sana as the Head of CNS Therapy
-
ProMIS Neurosciences’ Dr. Neil Cashman CSO, to Speak at 2020 ALS ONE Research SymposiumData supporting antibody and intrabody candidates that selectively target toxic TDP-43 while preserving normal protein highlighted
10/30/2020
ProMIS Neurosciences, Inc. announced that co-founder and Chief Scientific Officer Dr. Neil Cashman will deliver a presentation titled “TDP-43 Misfolding-Specific Antibodies in Treatment of TDP-43 Mediated Diseases” on November 5th at the virtual ALS ONE Research Symposium.
-
Two Landmark Studies Advance Focused Ultrasound Treatment for Parkinson's Disease
10/30/2020
A team of researchers in Madrid, Spain, and another team in Toronto, Canada, are the first in the world to use focused ultrasound technology to target a new area of the brain in patients with Parkinson's disease and potentially curb, or even reverse, its progression.
-
THOR-707 is a non-alpha IL-2 candidate that is currently being studied in Phase I trials in solid tumors.